Research programme: protein kinase inhibitors - Novartis/Vertex

Drug Profile

Research programme: protein kinase inhibitors - Novartis/Vertex

Alternative Names: VX-322; VX-398; VX-608

Latest Information Update: 24 Mar 2011

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Vertex Pharmaceuticals
  • Developer Novartis; Vertex Pharmaceuticals
  • Class Small molecules
  • Mechanism of Action Fms-like tyrosine kinase 3 inhibitors; Protein kinase inhibitors; Protein tyrosine kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Cancer; Cardiovascular disorders; Inflammation; Neurological disorders

Most Recent Events

  • 17 Nov 2004 Novartis has selected VX 322 for clinical development
  • 10 Feb 2004 Vertex and Novartis amend research agreement
  • 26 May 2000 Preclinical development for Cardiovascular disorders in USA (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top